• LAST PRICE
    10.7300
  • TODAY'S CHANGE (%)
    Trending Down-0.2400 (-2.1878%)
  • Bid / Lots
    10.9000/ 1
  • Ask / Lots
    11.3900/ 10
  • Open / Previous Close
    10.8900 / 10.9700
  • Day Range
    Low 10.4600
    High 11.3000
  • 52 Week Range
    Low 6.5400
    High 49.5150
  • Volume
    554,844
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Line Graph See accessible table below
News Volume Accessibility Table
DateIndex Fund Price vs. News Density
09/1$16.10
09/2$16.77
09/6$15.51
09/7$15.75
09/8$16.17
09/9$15.74
09/12$15.60
09/13$13.93
09/14$14.08
09/15$14.64
09/16$13.70
09/19$13.52
09/20$13.09
09/21$12.63
09/22$12.48
09/23$11.80
09/26$11.51
09/27$12.12
09/28$12.00
09/29$10.97
09/30$10.73
  • Sep 22, 2022

      Show headlines and story abstract
    • 8:50AM ET on Thursday Sep 22, 2022 by PR Newswire
      Companies Mentioned: MNMD, CMPS, NUMIF, ATAI

      FN Media Group Presents Microsmallcap.com Market Commentary

      Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminalized psychedelics, a meeting was held by the City Council's Public Safety and Legal Administration Committee to discuss a resolution that sought to replicate San Francisco's policies. The new bill would see police deprioritize enforcing law on people carrying psychedelic mushrooms and is part of a national effort to normalize the use of magic mushrooms and other plants as therapies for mental illness. Although the committee did not yet resolve to move the action forward, its members unanimously agreed to hold the measure for further study and continue discussing it in the next session. The decriminalization of psychedelics is good news for companies developing psychedelic-based treatments to combat mental illness, such as Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF), Atai Life Sciences N.V. (NASDAQ:ATAI), Compass Pathways (NASDAQ:CMPS), Mind Medicine (MindMed) Inc (NASDAQ:MNMD) (NEO:MMED), and Cybin Inc. (NYSE:CYBN).

  • Sep 19, 2022

  • Sep 7, 2022

      Show headlines and story abstract
    • 8:50AM ET on Wednesday Sep 07, 2022 by PR Newswire
      Companies Mentioned: MNMD, ENVB, CYBN, CMPS, OPTHF

      FN Media Group Presents Microsmallcap.com Market Commentary

      According to a new survey by Johns Hopkins Medicine researchers, people's attitudes toward death change after a psychedelic drug experience and a non-drug-related out-of-body experience. The researchers divided more than 3,000 participants into two groups: those who had already had an extraordinary drug-free experience and those who had used a psychedelic drug: psilocybin (found in magic mushrooms), lysergic acid diethylamide (LSD), ayahuasca or N,N-dimethyltryptamine (DMT). They found that about 90% of people in both groups feared death less than before their experiences. These findings are based on previous research demonstrating that psychedelics can relieve end-of-life anxiety, especially when combined with therapy. Companies developing psychedelic-based treatments include Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF), Compass Pathways (NASDAQ:CMPS), Mind Medicine (MindMed) Inc (NASDAQ:MNMD) (NEO:MMED), Cybin Inc (NYSE:CYBN) (NEO:CYBN), and Enveric Biosciences (NASDAQ:ENVB).

  • Sep 1, 2022